CLAIMS

1. The use of a compound that is *(R)*-2-(4-((2-ethoxy-3-(4-(trifluoromethyl)phenoxy)-propyl)thio)-2-methylphenoxy)acetic acid or a salt thereof in the manufacture of a medicament for treating homozygous familial hypercholesterolemia in a subject.

2. The use of claim 1 where the compound is *(R)*-2-(4-((2-ethoxy-3-(4-(trifluoromethyl)-phenoxy)propyl)thio)-2-methylphenoxy)acetic acid L-lysine dihydrate.

3. The use of claim 1 or 2 where the dose of the compound is 20-200 mg/day, when the dose is calculated as *(R)*-2-(4-((2-ethoxy-3-(4-(trifluoromethyl)phenoxy)propyl)thio)-2-methylphenoxy)acetic acid.

4. The use of claim 3 where the dose of the compound is 50-200 mg/day, when the dose is calculated as *(R)*-2-(4-((2-ethoxy-3-(4-(trifluoromethyl)phenoxy)propyl)thio)-2-methylphenoxy)acetic acid.

5. The use of any one of claims 1 to 4 where the medicament is to be administered once/day.

6. The use of any one of claims 1 to 5 where the medicament is to be administered alone.

7. The use of any one of claims 1 to 5 where the medicament is to be administered in combination with an MTP inhibitor.

8. The use of claim 7 where the MTP inhibitor is lomitapide or a salt thereof, SLx-4090, or JTT-130.

9. The use of claim 8 where the MTP inhibitor is lomitapide or a salt thereof.

10. The use of claim 9 where the dose of the lomitapide or a salt thereof is 10-100 mg/day, when the dose is calculated as lomitapide mesylate salt.

11. The use of any one of claims 7 to 10 where the MTP inhibitor is to be administered once/day.

12. The use of any one of claims 1 to 5 where the medicament is to be administered in combination with an apoB-100 synthesis inhibitor.

13. The use of claim 12 where the apoB-100 synthesis inhibitor is mipomersen or a salt thereof.

14. The use of claim 13 where the dose of the mipomersen or a salt thereof is 100-300 mg every week, when the dose is calculated as mipomersen sodium salt.

15. The use of any one of claims 1 to 5 where the medicament is to be administered in combination with a PCSK9 inhibitor.

16. The use of claim 15 where the PCSK9 inhibitor is evolocumab, alirocumab, bococizumab, RG7652, LGT-209, LY3015014, ALN-PCSsc, or BMS-962476.

17. The use of claim 16 where the PCSK9 inhibitor is evolocumab.

18. The use of claim 17 where the dose of evolocumab is 140 mg every 2 weeks or 420 mg every 4 weeks.

19. The use of claim 15 where the PCSK9 inhibitor is alirocumab.

20. The use of claim 19 where the dose of alirocumab is 150 mg every 2 weeks or 150, 200 or 300 mg every 4 weeks.

21. The use of claim 15 where the PCSK9 inhibitor is bococizumab.

22. The use of claim 21 where the dose of bococizumab is 50, 100, or 150 mg every 2 weeks or 200 or 300 mg every 4 weeks.